leisure time -WSS

leisure time

author：explore 2025-09-30 00:01:12 - browse：9914

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Where are patients getting their prescriptions for GLP

WSS

New case study details death in closely watched Alzhiemer's trial

Option Care buys Amedisys in $3.6 billion home care deal

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Maui funeral service workers on devastation of fires: 'I'm in shock'

Australia's humpback populations rebound raising hopes of marine scientists

Novo acquires Inversago for up to $1 billion

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Listen: Biogen's messy board & Laronde's data problem

Continuity nursing helped my family in our darkest PICU moments

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Medicare details structure of new drug price negotiation program

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Covid's long

Heart attack and stroke risk calculators need revising

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

leisure time

Kim Kardashian sparks debate on benefits of full

Target recalls 2.2 million additional candles due to laceration, burn hazards

When is a doctor not a doctor? Try when patients address women doctors

Maui funeral service workers on devastation of fires: 'I'm in shock'

New case study details death in closely watched Alzhiemer's trial

Kim Kardashian sparks debate on benefits of full

focus

hotspot

leisure time

focus